

Marcus O Butler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7104662/publications.pdf>

Version: 2024-02-01

92
papers

4,603
citations

147801

31
h-index

118850

62
g-index

93
all docs

93
docs citations

93
times ranked

6162
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
2	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	27.0	376
3	A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. <i>Nature Medicine</i> , 2018, 24, 352-359.	30.7	349
4	Adjuvant nivolumab versus ipilimumab in resected stage IIIb-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1465-1477.	10.7	330
5	Pembrolizumab. , 2015, 3, 36.		171
6	BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. <i>Journal of Clinical Investigation</i> , 2016, 126, 3479-3494.	8.2	168
7	Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. <i>Blood</i> , 2006, 107, 1528-1536.	1.4	156
8	Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell. <i>Clinical Cancer Research</i> , 2007, 13, 1857-1867.	7.0	123
9	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3003-3003.	1.6	120
10	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173776.	7.1	116
11	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	4.1	115
12	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	6.4	114
13	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 415.	2.8	114
14	Autoantibodies frequently detected in patients with aplastic anemia. <i>Blood</i> , 2003, 102, 4567-4575.	1.4	105
15	Human cell-based artificial antigen-presenting cells for cancer immunotherapy. <i>Immunological Reviews</i> , 2014, 257, 191-209.	6.0	96
16	Establishment of Antitumor Memory in Humans Using in Vitro-Educated CD8 T Cells. <i>Science Translational Medicine</i> , 2011, 3, 80ra34.	12.4	94
17	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	4.2	94
18	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. <i>Science Immunology</i> , 2019, 4, .	11.9	85

#	ARTICLE	IF	CITATIONS
19	Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 926-936.	3.4	73
20	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	12.8	63
21	Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. <i>Clinical Cancer Research</i> , 2019, 25, 6052-6060.	7.0	61
22	Immune modulator-induced changes in the gastrointestinal tract. <i>Histopathology</i> , 2017, 71, 494-496.	2.9	56
23	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1186-1192.	6.4	50
24	Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma. <i>Cancer Immunology Research</i> , 2018, 6, 1001-1007.	3.4	50
25	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020, 11, 6262.	12.8	50
26	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. <i>Clinical Cancer Research</i> , 2018, 24, 6168-6174.	7.0	44
27	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. <i>Clinical Cancer Research</i> , 2017, 23, 4992-5002.	7.0	41
28	A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. <i>International Immunology</i> , 2010, 22, 863-873.	4.0	39
29	Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). <i>Clinical Cancer Research</i> , 2020, 26, 804-811.	7.0	39
30	Efficient Presentation of Naturally Processed HLA Class I Peptides by Artificial Antigen-Presenting Cells for the Generation of Effective Antitumor Responses. <i>Clinical Cancer Research</i> , 2006, 12, 2967-2975.	7.0	38
31	Transient stimulation expands superior antitumor T cells for adoptive therapy. <i>JCI Insight</i> , 2017, 2, e89580.	5.0	37
32	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9522-9522.	1.6	37
33	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
34	Specific Roles of Each TCR Hemichain in Generating Functional Chain-Centric TCR. <i>Journal of Immunology</i> , 2015, 194, 3487-3500.	0.8	35
35	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. <i>Oncology Letters</i> , 2016, 11, 1581-1585.	1.8	34
36	Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells. <i>Journal of Autoimmunity</i> , 2019, 97, 10-21.	6.5	34

#	ARTICLE	IF	CITATIONS
37	Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help. PLoS ONE, 2012, 7, e30229.	2.5	31
38	Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. Cancer Immunology Research, 2015, 3, 1070-1081.	3.4	29
39	<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. International Journal of Gynecological Cancer, 2019, 29, 346-352.	2.5	29
40	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 2022, 40, 1939-1948.	1.6	29
41	HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway. Nature Communications, 2017, 8, 15244.	12.8	28
42	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. , 2021, 9, e001642.		28
43	Development of the Functional Assessment of Cancer Therapyâ€œImmune Checkpoint Modulator (FACTâ€œICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer, 2020, 126, 1550-1558.	4.1	26
44	Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience. Melanoma Research, 2018, 28, 571-577.	1.2	25
45	Induction of HLA-DP4â€œRestricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell. Clinical Cancer Research, 2011, 17, 5392-5401.	7.0	24
46	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. Obstetrics and Gynecology International, 2018, 2018, 1-10.	1.3	23
47	DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. Nature Communications, 2018, 9, 1915.	12.8	21
48	Cancer patientsâ€™ experiences with immune checkpoint modulators: A qualitative study. Cancer Medicine, 2020, 9, 3015-3022.	2.8	21
49	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research, 2021, 27, 5280-5288.	7.0	21
50	Identification of an immunogenic CD8+ T-cell epitope derived from Î³-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood, 2006, 108, 2662-2668.	1.4	19
51	Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21. Clinical Cancer Research, 2008, 14, 6125-6136.	7.0	18
52	A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs. Journal of Immunology, 2018, 200, 500-511.	0.8	17
53	Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nature Immunology, 2022, 23, 1273-1283.	14.5	17
54	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical Cancer Research, 2020, 26, 2477-2486.	7.0	16

#	ARTICLE	IF	CITATIONS
55	Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. <i>Nature Biotechnology</i> , 2021, 39, 958-967.	17.5	15
56	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. <i>Clinical Cancer Research</i> , 2017, 23, 4980-4991.	7.0	14
57	Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. <i>Current Oncology</i> , 2021, 28, 2173-2179.	2.2	14
58	CD4+ and CD8+ TCR β repertoires possess different potentials to generate extraordinarily high-avidity T cells. <i>Scientific Reports</i> , 2016, 6, 23821.	3.3	13
59	Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. <i>ELife</i> , 2020, 9, .	6.0	13
60	CDR3 β sequence motifs regulate autoreactivity of human invariant NKT cell receptors. <i>Journal of Autoimmunity</i> , 2016, 68, 39-51.	6.5	12
61	IL-21 Can Supplement Suboptimal Lck-Independent MAPK Activation in a STAT-3 β -Dependent Manner in Human CD8+ T Cells. <i>Journal of Immunology</i> , 2012, 188, 1609-1619.	0.8	10
62	New treatments for metastatic melanoma. <i>Cmaj</i> , 2014, 186, 754-760.	2.0	9
63	Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly. <i>Scientific Reports</i> , 2018, 8, 4804.	3.3	8
64	Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator β 's choice (IC) in first-line metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9527-9527.	1.6	8
65	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 818679.	2.8	8
66	Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. <i>Cancers</i> , 2021, 13, 2282.	3.7	6
67	Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. <i>Melanoma Research</i> , 2021, 31, 27-37.	1.2	6
68	Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma. <i>MDM Policy and Practice</i> , 2022, 7, 238146832210896.	0.9	5
69	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. <i>Cancers</i> , 2022, 14, 89.	3.7	5
70	Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9579-9579.	1.6	5
71	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	2.9	4
72	Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 3640.	3.7	4

#	ARTICLE	IF	CITATIONS
73	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2022, 160, 1-11.	2.8	4
74	Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice. <i>Radiotherapy and Oncology</i> , 2022, 168, 89-94.	0.6	4
75	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
76	Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors. <i>PLoS ONE</i> , 2016, 11, e0156114.	2.5	3
77	Key Residues at Third CDR3 ² Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs. <i>Journal of Immunology</i> , 2017, 198, 1056-1065.	0.8	3
78	Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2528-2528.	1.6	3
79	Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGF β 2 inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2524-2524.	1.6	3
80	Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	2
81	Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87. <i>Journal of Autoimmunity</i> , 2019, 102, 114-125.	6.5	2
82	The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2589-2589.	1.6	2
83	Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming. <i>Journal of Neuroimmunology</i> , 2020, 346, 577267.	2.3	1
84	Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center. <i>JCO Oncology Practice</i> , 2022, , OP2100810.	2.9	1
85	Off the Shelf, GMP Grade Artificial APC Efficiently Generates Large Numbers of Antigen Specific CTLs Sufficient for the Treatment of Cancer and Infectious Disease.. <i>Blood</i> , 2004, 104, 3172-3172.	1.4	0
86	Highly Efficient Presentation of Endogenously Processed Class I Peptides by Artificial APC for the Generation of Effective Anti-Tumor Responses.. <i>Blood</i> , 2004, 104, 1355-1355.	1.4	0
87	β -Globin, a Tumor-Associated Antigen for Juvenile Myelomonocytic Leukemia (JMML): A Cell-Based Approach To Identify Tumor Antigenic Epitopes That Are Naturally Processed and Presented.. <i>Blood</i> , 2004, 104, 3418-3418.	1.4	0
88	The addition of fludarabine to cyclophosphamide for lymphodepleting chemotherapy enhances the persistence of infused NY-ESO-1 TCR anticancer therapy TBI-1301.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2539.	1.6	0
89	Study design of a global molecular disease characterization initiative (MDCI) in oncology clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13598-e13598.	1.6	0
90	Real-world changes in the clinical management of resected stage III melanoma at high risk of local recurrence in the era of modern systemic therapies.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21575-e21575.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Reply to M.Z. Farooq et al. JCO Oncology Practice, 0, , .	2.9	0
92	Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2022, 40, e18630-e18630.	1.6	0